Erythropoiesis-stimulating agents in chronic kidney disease: What have we learned in 25 years?  by Hung, Szu-Chun et al.
Journal of the Formosan Medical Association (2014) 113, 3e10Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.jfma-onl ine.comREVIEW ARTICLEErythropoiesis-stimulating agents in chronic
kidney disease: What have we learned in 25
years?Szu-Chun Hung a, Yao-Ping Lin b,c, Der-Cherng Tarng d,e,*aDivision of Nephrology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Buddhist
Tzu Chi University, Taipei, Taiwan
bDepartment of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
c School of Medicine, National Yang-Ming University, Taipei, Taiwan
dDivision of Nephrology, Department of Medicine, and Immunology Research Center, Taipei Veterans
General Hospital, Taipei, Taiwan







hemodialysisThe authors have no conflicts of in
* Corresponding author. Division of N
Taipei 112, Taiwan.
E-mail address: dctarng@vghtpe.g
0929-6646/$ - see front matter Copyr
http://dx.doi.org/10.1016/j.jfma.201Since the pioneering studies by Eschbach et al in 1987, erythropoiesis-stimulating agents (ESAs)
have become the mainstay of anemia therapy in chronic kidney disease (CKD) patients. The
introduction of ESAs 25 years ago markedly improved the lives of many patients with CKD,
who until then had severe, often transfusion-dependent anemia. However, randomized
controlled trials demonstrate an increased risk for cardiovascular events such as stroke, throm-
bosis, and death at nearly normal hemoglobin concentrations and higher ESA doses in CKD. By
contrast, kidney transplant recipients may represent a unique population of CKD patients who
may benefit from ESA therapy. This review discusses potential mechanisms involving the eryth-
ropoietic and nonerythropoietic effects of ESA treatment and ESA resistance. Further research
aimed at elucidating the causal pathways is strongly recommended. Given current knowledge,
however, clinical practice should avoid disproportionately high dosages of ESAs to achieve re-
commended hemoglobin targets, particularly in those with significant cardiovascular morbidity
or ESA resistance. The key to CKD anemia management will be individualization of the potential
benefits of reducing blood transfusions and anemia-related symptoms against the risks of harm.
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in their degree of glycosylation and the types of glycanErythropoiesis-stimulating agents (ESAs) and adjuvant iron
therapy have been the primary treatments for anemia in
chronic kidney disease (CKD). It was assumed that
increasing hemoglobin concentrations would not only
improve patient-perceived quality of life (i.e., fatigue,
energy level, and physical functioning) and reduce the
need for blood transfusions, as shown in early trials1e3 but
also reduce morbidity and mortality. However, multi-
center trials have challenged this traditional paradigm,
particularly in regard to ESAs. Use of ESAs to normalize
hemoglobin levels has repeatedly been shown to be
associated with an increased risk of cardiovascular events
and death. Anemia management patterns have changed
markedly between 2002 and 2008 in hemodialysis patients
in the USA.4 Clinicians are prescribing fewer ESAs and
more intravenous iron after changes to ESA drug labels
and a new prospective payment system for dialysis ser-
vices. The clinical impact of these changes needs further
evaluation.
Over the past 2 decades, ESAs, particularly recombinant
human erythropoietin (rHuEPO), have become the
mainstay of renal anemia therapy (Table 1).51,52,7,8,14,1,9,
15,53,16,17,34,18,21,22,12,13 Erythropoietin (EPO) is the prin-
cipal hormone involved in the regulation and maintenance
of a physiological level of circulating erythrocyte mass. EPO
exerts its biological effect primarily by attaching to the EPO
receptors on erythroid progenitor cells, which leads to
differentiation into mature erythrocytes. Human EPO is a
165-amino acid glycoprotein mainly produced by the liver
during fetal life and by fibroblast-like peritubular intersti-
tial cells in the kidney in adulthood. Interstitial pericytes
are myofibroblast progenitors in fibrotic kidney disease. It is
possible that in the progression of CKD, the EPO-producing
abilities of pericytes are abated during the peri-
cyteemyofibroblast transition, leading to the decreased
production of EPO. It is also possible that uremic toxin
accumulation can induce DNA methylation, a kind of
epigenetic modification, which is involved in the silencing
of the EPO gene.5
Recent evidence suggests that CKD anemia might be
due to defective hypoxic signaling rather than an
inability of the EPO-producing cells to synthesize EPO.
Bernhardt et al6 demonstrated that pharmacologic
hypoxia-inducible transcription factor (HIF) stabilization
using competitive prolyl-hydroxylase inhibitors (PHIs)
can induce endogenous EPO in dialysis patients. The
clinical trial of HIF-PHIs for patients with CKD anemia is
ongoing. The long-term safety of therapeutic activation
of the HIF system requires further study because of the
broad biological potential of HIF in mediating hypoxia
responses.
Development of ESA
In 1977, Miyake et al7 purified EPO from the urine of pa-
tients with severe aplastic anemia. In 1983, Dr Fu-Kuen
Lin8 from Taiwan successfully established the genetic
code for EPO, which led to the development of rHuEPO.
Epoetin a and b, the first generation rHuEPOs, arecomposed of an identical amino acid sequence, but differ
moieties. Initially, rHuEPO was only given intravenously.
The preferred route of application has been subcutaneous
in recent years because it facilitates self-administration
and is associated with substantial dose reduction. Subse-
quently, two second-generation ESAs with an extended
duration of action were developeddhyperglycosylated
version of epoetin a, darbepoetin a, and a pegylated
version of epoetin b, methoxy polyethylene glycol-epoetin
b (also known as continuous erythropoietin receptor
activator or CERA). Darbepoetin a is approved for dosing
every 2 weeks and CERA for dosing once a month. Dosage
requirements of darbepoetin a and CERA do not appear to
differ between the intravenous and subcutaneous routes
of administration.
An extremely rare but serious adverse effect of the
long-term administration of rHuEPO is pure red cell
aplasia (PRCA).9 rHuEPO, although weakly immunogenic,
may induce the production of immunoglobulin (Ig)G anti-
bodies against not only the recombinant molecules, but
also residual endogenous EPO. Therefore, the resulting
anemia is much more severe than prior to the onset of
therapy. Bone marrow examination shows almost com-
plete absence of erythroid precursors, but normal white
cell and platelet precursors. PRCA has been observed
predominantly with subcutaneous use of epoetin a after
human serum albumin was removed from the formulation
and replaced with Tween 80 to avoid potential contami-
nation by viruses and prions. It has been postulated that
this change in formulation might have reduced its
stability.10
Peginesatide, a synthetic peptide-based ESA, is immu-
nologically distinct from EPO and has been used as a rescue
therapy in patients who develop rHuEPO-induced PRCA.11
Recent trials demonstrated that peginesatide was as
effective as epoetin a in maintaining hemoglobin levels and
had a comparable cardiovascular safety profile in patients
undergoing hemodialysis.12 However, cardiovascular events
and mortality were increased with peginesatide, as
compared with darbepoetin, in patients with CKD stages 3,
4, or 5 who were not undergoing dialysis.13ESA, once a promising cure for CKD anemia
In 1986, Winearls et al14 found that rHuEPO was effective
for treating anemia in patients who were on chronic he-
modialysis. Nevertheless, important safety concerns arose
even in this first report of the human use of EPO. During
treatment, 1 of 10 study patients had an episode of hy-
pertensive encephalopathy and 2 patients had clotting in
their arteriovenous fistulas. The authors concluded that
longer-term observations are needed to determine the
consequences of increasing the hematocrit. In 1989, a
Phase III multicenter clinical trial by Eschbach et al3 was
conducted to determine the effectiveness and safety of
rHuEPO in anemic patients with end-stage renal disease. In
a single-arm study, 333 hemodialysis patients with uncom-
plicated anemia (hematocrit 30%) were enrolled to receive
epoetin a intravenously, three times/week at 150 U/kg or
300 U/kg body weight, which was then reduced to 75 U/kg
Table 1 Milestones in the use of erythropoiesis-
stimulating agents in chronic kidney disease.
1836 Bright described anemia as a complication
of renal failure51
1957 Jacobson et al established that the kidney
produces EPO52
1977 Miyake et al purified human EPO from the
urine of patients with aplastic anemia7
1983 Lin et al cloned and expressed the human
EPO gene8
1986 Winearls et al reported the first use of
rHuEPO for anemia in patients on chronic
hemodialysis14
1987 Eschbach et al reported the correction of
anemia of end-stage renal disease with
rHuEPO. Results of a combined phase I and
II clinical trial1
1989 FDA approval of the first rHuEPO for the
treatment of renal anemia
1996 PRCA reported9
1998 Normal Hematocrit Trial15
2001 FDA approval of Aranesp (darbepoetin a)
2006 KDOQI guideline for anemia in CKD53
2006 CREATE and CHOIR studies16,17
2007 FDA approval of MIRCERA
2007 DRIVE study34
2009 TREAT study18
2011 FDA modifies dosing recommendations for
ESAs
2012 KDIGO Clinical Practice Guideline for Anemia
in CKD21
2012 CAPRIT study22
2013 EMERALD and PEARL studies12,13
CAPRIT Z Correction of Anemia and Progression of Renal
Insufficiency in Transplant Patients; CHOIR Z Correction of
Hemoglobin and Outcomes in Renal Insufficiency;
CKD Z chronic kidney disease; CREATE Z Cardiovascular risk
Reduction by Early Anemia Treatment with Epoetin b;
DRIVE Z Dialysis Patients’ Response to IV Iron with Elevated
Ferritin; EMERALDZ Efficacy and Safety of Peginesatide for the
Maintenance Treatment of Anemia in Patients with Chronic
Renal Failure Who Were Receiving Hemodialysis and Were Pre-
viously Treated with Epoetin; EPO Z erythropoietin;
ESAZ erythropoiesis-stimulating agents; FDAZ Food and Drug
Administration; KDIGO Z Kidney Disease: Improving Global
Outcomes; KDOQI Z Kidney Disease Outcomes Quality Initia-
tive; MIRCERA Z methoxy polyethylene glycol-epoetin beta;
PEARL Z Peginesatide for the Correction of Anemia in
Patients with Chronic Renal Failure Not on Dialysis and Not
Receiving Treatment with Erythropoiesis-Stimulating Agents;
PRCA Z pure red cell aplasia; rHuEPO Z recombinant human
erythropoietin; TREATZ Trial to Reduce Cardiovascular Events
with Aranesp Therapy.
ESAs in CKD 5and adjusted to maintain the hematocrit at 35%. Erythro-
cyte transfusions were eliminated in all patients within 2
months of therapy. Furthermore, the study patients expe-
rienced significant improvements in quality of life. The US
Food and Drug Administration (FDA) approved the use of
epoetin a for the treatment of renal anemia in dialysispatients in June 1989. However, 35% of the study patients
experienced an increase in their blood pressure. Seizures,
probably due to hypertensive encephalopathy, occurred in
5.4% of the patients. Almost half of the study patients
developed iron deficiency and their platelet counts
increased slightly, a finding with unclear clinical signifi-
cance at that time.Can one desire too much of a good thing?
Normal Hematocrit Trial
Although it was widely accepted that the ability of ESAs to
increase hemoglobin concentrations was a suitable surro-
gate for hard study endpoints, investigators began working
on the design of an outcome trial for hemodialysis patients
that would examine the safety concerns raised by earlier
studies. In 1993, 1233 eligible hemodialysis patients with
clinical evidence of congestive heart failure or ischemic
heart disease were enrolled in a randomized study (Normal
Hematocrit Trial) to assess the risks and benefits of
normalizing the hematocrit.15 A total of 618 patients were
assigned to receive increasing doses of epoetin a to achieve
and maintain a hematocrit of 42%, and 615 were assigned to
receive doses of epoetin a sufficient to maintain a hemat-
ocrit of 30% throughout the study. The primary endpoint
was time to death or first nonfatal myocardial infarction.
Unfortunately and unexpectedly, the trial was stopped
early because there was a strong trend toward increased
mortality or nonfatal myocardial infarction in those
assigned to a higher hematocrit target (hazard ratio, 1.3;
95% confidence interval, 0.9e1.9). Moreover, the patients
in the normalization arm experienced significantly higher
rates of vascular access thrombosis (39% vs. 29% in the
control group). Thus, the Normal Hematocrit Trial contra-
dicted the expectation that a higher physiological hemat-
ocrit concentration would yield reduced morbidity and
mortality.
CHOIR and CREATE study
In 2006, approximately a decade after the Normal He-
matocrit Trial, two similar randomized trials in patients
with advanced CKD were presented. Both studies explored
the hypothesis that targeting a normal hemoglobin con-
centration would reduce cardiovascular events in CKD pa-
tients with anemia. The Correction of Hemoglobin and
Outcomes in Renal Insufficiency (CHOIR) study was
terminated early on safety grounds.16 Patients [n Z 1432,
with estimated glomerular filtration rate (eGFR)
15e50 mL/min/1.73 m2] were randomly assigned to
receive epoetin a to achieve a hemoglobin level of 13.5 g/
dL versus 11.3 g/dL. The patients treated for the higher
hemoglobin target experienced a 34% increased risk of a
composite cardiovascular endpoint compared to those
treated for a lower hemoglobin target. In addition, quality
of life did not differ between the groups. The Cardiovas-
cular risk Reduction by Early Anemia Treatment with
Epoetin b (CREATE) study used epoetin b in 603 patients
(eGFR 15e35 mL/min/1.73 m2) to target hemoglobin con-
centrations of 13e15 g/dL or 11e12.5 g/dL.17 The com-
posite cardiovascular endpoint did not differ between the
two groups. There was a significant improvement in certain
6 S.-C. Hung et al.measures of quality of life (general health, vitality).
However, the risk of end-stage renal disease increased in
the higher target group. On the basis of these two studies,
the FDA mandated the addition of a black box warning and
change of the labels of ESAs to reflect a lower target he-
moglobin range of 10e12 g/dL.
TREAT study
In November 2009, the results from the Trial to Reduce
Cardiovascular Events with Aranesp Therapy (TREAT) were
presented.18 TREAT, a large trial of 4038 patients with
diabetes, CKD (eGFR 20e60 mL/min/1.73 m2), and anemia,
randomly assigned participants into receiving darbepoetin
for a hemoglobin target of 13 g/dL, or matching placebo
with rescue darbepoetin treatment below a hemoglobin of
9 g/dL. Despite having achieved excellent separation in the
mean hemoglobin concentrations between the groups, the
incidence of the composite cardiovascular endpoint did not
differ. There was a significant improvement in quality of
life (FACTeFatigue score), but a doubling in the risk of
stroke in the normal hemoglobin arm provides support for
an adverse relationship between ESAs and stroke.
Furthermore, increased cancer-related mortality associ-
ated with darbepoetin therapy was consistent with findings
in a recent meta-analysis.19
In summary, the results from CHOIR, CREATE, and
TREAT trials all demonstrated an increased risk of
adverse outcomes at higher hemoglobin concentrations
and higher ESA dosage. In June 2011, the FDA recom-
mended more conservative dosing guidelines for ESAs
when used to treat anemia in patients with CKD.20 In
August 2012, the Kidney Disease: Improving Global Out-
comes (KDIGO) Anemia Guideline was published.21 This
recommended that for patients with CKD anemia not on
dialysis, ESA treatment should only be considered when
the hemoglobin level is < 10 g/dL and be individualized
based on the rate of fall of hemoglobin, prior response to
iron therapy, the risk of needing a transfusion, the risks
related to ESA therapy, and the presence of symptoms
attributable to anemia. For patients with anemia from
CKD on dialysis, ESA treatment should be initiated when
the hemoglobin level is 9e10 g/dL to avoid having the
hemoglobin concentration fall below 9.0 g/dL. As some
patients may have improvements in quality of life at
higher hemoglobin concentration, ESA therapy may be
started > 10.0 g/dL. In general, ESAs should not be used
to maintain a hemoglobin concentration > 11.5 g/dL in
adult patients with CKD.ESA in transplant anemia
Whether these findings can be extrapolated to kidney
transplant recipients is unclear. Given the presence of an
allograft and the ongoing need for immunosuppressants,
the pathogenesis of anemia and response to ESAs in this
population is likely to be different from the general CKD
population. The Correction of Anemia and Progression of
Renal Insufficiency in Transplant Patients (CAPRIT) study
is a 2-year, randomized, controlled, open-label, multi-
center trial of EPO treatment in anemic kidney trans-
plant recipients with moderate graft dysfunction(defined as estimated creatinine clearance < 50 mL/
min/1.73 m2 using the CockcrofteGault formula).22 The
primary endpoint was the change in eGFR. There was a
significant reduction in the rate of progression to chronic
allograft nephropathy and an improvement in the quality
of life when targeting a hemoglobin  13 g/dL in kidney
transplant recipients. The number of cardiovascular
events was low and similar between the groups. The
kidney transplant population may represent a unique
population of CKD patients who may benefit from ESA
therapy, although the underlying mechanism by which
correction of anemia with ESAs preserves renal function
is unclear.23 The nephroprotective effects of EPO may be
at least partly caused by the inhibition of calcineurin
inhibitor-mediated epithelial to mesenchymal transition
by EPO.24 The safety results of the CAPRIT study are in
apparent discrepancy with an observational study that
showed that increasing hemoglobin concentrations to >
14 g/dL with EPO was significantly associated with an
increase in mortality in 1794 renal transplant recipients
recorded in the Austrian Dialysis and Transplant
Registry.25 Although these two studies cannot be
compared because of their different designs and popu-
lation characteristics, it should be noted that the mean
hemoglobin concentration in the normalization group in
the CAPRIT study was 12.9 g/dL, which is less than the
cutoff associated with higher mortality in the observa-
tional study.
Higher ESA doses might cause harm, but what is the
mechanism?
It is unclear whether the negative effects of complete
correction of anemia are due primarily to high hemoglobin
levels per se, to excessive ESA doses, or to both. Secondary
analysis of the Normal Hematocrit Trial and the CHOIR trial
found adverse outcomes among the normal hemoglobin
target groups and also found that higher attained hemo-
globin concentrations were not associated with higher
risks,15,26 leading to the hypotheses that higher doses of
epoetin may have been deleterious. Higher doses of ESAs
might be associated with toxicities, which include eryth-
ropoietic and nonerythropoietic effects.
Erythropoietic effects of ESA
Hyperviscosity
The sustained dose-dependent rise in hemoglobin produced
by ESA effectively abolishes symptoms of anemia, but at
the cost of an increase in blood viscosity. This in turn pre-
disposes patients to increased vascular resistance and the
development of hypertension.27 Although the study by
Goodkin et al28 provides evidence that a naturally occurring
higher hemoglobin concentration (> 12 g/dL, defined as
endogenous EPO patients) does not increase mortality
among hemodialysis patients, only 1.8% of the study pop-
ulation met the criteria to be included in the endogenous
EPO group. After adjustment for case mix, there was no
difference between groups (relative risk, 0.98; 95% confi-
dence interval, 0.80e1.19). Cystic disease was more com-
mon in the endogenous EPO group and diabetes in the other
ESAs in CKD 7group, but the impact of end-stage renal disease etiology
may not have been fully accounted for in the adjusted
models.
The leading cause of both morbidity and mortality in
patients with CKD is cardiovascular disease, for which hy-
pertension is a well-established risk factor. Therefore, ESA-
related hypertension is of particular concern. However, can
we correct anemia to alleviate symptoms by ESAs without
incurring the undue risk of hypertension? In a series of 202
consecutive hemodialysis patients, Hampl et al29 combined
optimized antihypertensive therapies, including b-blockers,
angiotensin-converting enzyme inhibitors, and angiotensin
receptor blockers, to target doses with full anemia
correction by epoetin b (hemoglobin target: males 14.5 g/
dL, females 13.5 g/dL). There was a significant reduction in
the left ventricular mass index, an improvement in the left
ventricular ejection fraction, and an improvement in the
New York Heart Association (NYHA) class from baseline to
follow-up in the overall study population. Therefore, it
seems that aggressive cardiovascular risk reduction thera-
pies should be incorporated in ESA treatment for CKD
anemia to ameliorate the associated adverse effects of
hyperviscosity.
Thrombocytosis
Streja et al30 hypothesized that the increased mortality
in hemodialysis patients with increased hemoglobin levels
due to the use of ESAs was caused by reactive thrombo-
cytosis resulting from iron deficiency. In their retrospec-
tive study of more than 40,000 hemodialysis patients,
relative thrombocytosis (defined as platelet count >
300  109/L) was seen in 15% of the patient population
and was associated with a 30% greater weekly dose of
ESA, lower transferrin saturation, and lower serum
ferritin concentration. Patients with a high hemoglobin
level (> 13.0 g/dL) who also had relative thrombocytosis
had a relative risk of all-cause mortality of 1.22
compared to similar patients without thrombocytosis.
The patients with thrombocytosis had an increased death
rate at all hemoglobin levels compared to patients
without thrombocytosis. If the hypothesis of Streja et al30
is correct, increasing the use of intravenous iron to help
prevent iron deficiency may reduce the number of pa-
tients with reactive thrombocytosis, thus reducing
thrombotic complications and mortality. A decrease in
mortality has been suggested in hemodialysis patients
receiving any intravenous iron up to a maximum dose of
400 mg/month.31
Iron deficiency in patients with CKD may indicate low
iron stores and impaired iron delivery associated with
inflammation.32 Hepcidin, a small peptide produced by the
liver, may play a pivotal role in the link between anemia
and inflammation in CKD. Hepcidin is induced by inflam-
mation and iron loading. Through the regulation of ferro-
portin, hepcidin limits iron availability for erythropoiesis by
inhibiting intestinal iron absorption and iron release from
the liver and reticuloendothelial system.33 To date, the
only definitive way in clinical practice to prove the pres-
ence of iron deficiency in CKD is to evaluate the erythro-
poietic response to iron administration. Data from the
Dialysis Patients’ Response to IV Iron with Elevated Ferritin
(DRIVE) study supports the value of intravenous iron inimproving hemopoietic response, even in patients with a
high baseline ferritin level.34Nonerythropoietic effects of ESA
Hypertension
Supraphysiologic doses of ESAs, especially at very high
doses, have off-target effects in other cell types expressing
EPO receptors, including endothelial cells.35 Liu et al36
demonstrated that EPO increases expression and function
of transient receptor potential canonical 5 (TRPC5) chan-
nels in cultured human endothelial cells and in monocytes
from hemodialysis patients. Upregulated TRPC5 might have
functional relevance in the pathogenesis of EPO-induced
hypertension in patients with CKD.36 The non-
erythropoietic functions of EPO might be transduced by a
receptor distinct of that found on erythroid cells. It has
been speculated that in extrahematopoietic tissues the EPO
receptor is a heterodimer with one EPO receptor monomer
and the common bc-subunit that is shared by the IL-3, IL-5,
and granulocyte-macrophage colony-stimulating factor
receptors.37
Intimal hyperplasia
Recently, Janmaat et al38 showed that EPO induces endo-
thelial platelet-derived growth factor BB (PDGF-BB)
expression. Enhanced levels of PDGF-BB subsequently
stimulate smooth muscle cell (SMC) proliferation in mice,
but no association was observed between hemoglobin levels
and SMC-rich neointima size. Stimulation of cultured
endothelial cells with EPO alone did not affect mRNA
expression levels of PDGF-BB, but cotreatment of cultured
endothelial cells with tumor necrosis factor a and EPO re-
sults in a significant induction of PDGF-BB expression. These
data indicate that EPO induces endothelial PDGF-BB
expression and accelerates SMC proliferation only in the
setting of ongoing inflammation, rather than the involve-
ment of EPO in the initiation of atherosclerosis. These re-
sults prompt caution with the use of EPO in certain clinical
scenarios. Patients with existing SMC-rich lesions and those
who are at risk of developing such lesions, such as CKD
patients who have received a stent, may have an elevated
risk to develop neointimal hyperplasia upon EPO treatment.
Tumor progression
Recent clinical trials have suggested increased adverse
events and reduced survival in ESA-treated cancer patients,
potentially related to EPO-induced tumor progression.39 It
has been proposed that EPO promotes tumor growth
through paracrine stimulation of tumor angiogenesis by
direct induction of endothelial cell proliferation and
migration, and endocrine stimulation of hematopoiesis
leading to increased oxygen supply and protection against
tumor-associated anemia. Additionally, the EPO receptor is
expressed on certain types of tumor cells and direct EPO/
EPO receptor interactions might mediate effects on
growth, survival, or apoptosis of tumor cells.40 Therefore,
the present American Society of Hematology and the
American Society of Clinical Oncology guidelines state that
ESA use should be limited in oncology and patients moni-
tored more closely.41
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Although relative EPO deficiency may contribute to the
anemia of CKD, it is not the only cause. Indeed, anemia of
CKD is resistant to ESAs in approximately 10e20% of pa-
tients. Patients needing greater doses are those with
concomitant infectious, inflammatory, or malignant condi-
tions resulting in relative ESA resistance, which may
contribute to increased mortality risk. Actually, the excess
of prespecified events in the high hemoglobin arm in the
Normal Hematocrit Trial and TREAT study occurred largely
in resistant patients who received high epoetin doses but
failed to achieve the target hemoglobin level.42
Using the lowest possible ESA dose to achieve the he-
moglobin target should be the focus of management of CKD
anemia. Therefore, maneuvers that maintain ESA respon-
siveness should be aggressively pursued. These include
optimizing the adequacy of dialysis,43 intravenous iron
therapy,44 suppressing any inflammation, treating hyper-
parathyroidism, and excluding occult bleeding. Switching
patients to alternative dialysis modalities, such as hemo-
diafiltration, results in lower ESA doses.45 Pentoxifylline46
and intravenous ascorbic acid47,48 as adjuvant therapies
for ESA treatment will also result in lower ESA doses
without causing a drop in the hemoglobin concentration.Use of ESAs in CKD patients: Think different
ESAs are among the earliest and most successful examples
of biotechnologically manufactured products to be used in
clinical medicine. However, the latest trials and meta-
analyses also illustrate how easy it is to assume that clinical
benefits must follow therapeutic interventions.49 Pioneer-
ing studies by Eschbach et al1e3 showed the effectiveness
of treating anemia of CKD with ESAs and led to more
aggressive therapy for anemia in an effort to improve sur-
vival for CKD patients. Contrary to expectations, clinical
trials do not confirm the benefits of an aggressive correc-
tion but suggest that it may be harmful.15e18 These results
lead us to rethink the use of ESAs for CKD anemia. Is giving
EPO to hyporesponsive patients bad? Is there an ESA class
effect? Is a hemoglobin target appropriate for all CKD pa-
tients? Should peritoneal dialysis patients have the same
hemoglobin targets as hemodialysis patients? Should the
goals of ESA therapy incorporate the effect of the treat-
ment on the patient-perceived quality of life?50 Many
important questions remain unanswered; thus, additional
trials are clearly needed.Conclusion
CKD anemia is a complex process due to relative EPO
deficiency, EPO resistance, and disorders of iron homeo-
stasis. Optimal management of CKD anemia remains a
challenge to clinicians. The following are what we have
learned in 25 years of ESA treatment for CKD anemia:
(1) In CKD patients with asymptomatic anemia or those
with mild fatigue, non-ESA-based strategies should be
adopted.(2) ESA therapy targeting higher hemoglobin levels (> 13 g/
dL) leads to increased risks of vascular and fatal events
compared to therapy targeting lower levels (11.5 g/dL).
(3) Maintain ESA responsiveness and use the lowest
possible ESA dose to achieve the recommended hemo-
globin target.
(4) Achieve regression of left ventricular hypertrophy, the
most important predictor of sudden cardiac death, by
combining aggressive cardiovascular risk reduction
therapies during ESA treatment.
(5) Use intravenous iron therapy during the correction of
renal anemia by ESA to prevent iron deficiency-induced
reactive thrombocytosis.
(6) Treat anemic CKD patients as individuals. In CKD pa-
tients who are unable to reach target hemoglobin levels
with usual ESA doses, the continuous increase in ESA
dosage to very high levels may be detrimental. By
contrast, CKD patients with few comorbidities, a low
degree of inflammation, and no malnutrition and
transplant candidates may benefit from higher hemo-
globin targets. These benefits include a better quality
of life and avoidance of allosensitization due to
frequent blood transfusions.References
1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW.
Correction of the anemia of end-stage renal disease with re-
combinant human erythropoietin. Results of a combined
phase I and II clinical trial. N Engl J Med 1987;316:73e8.
2. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW.
Treatment of the anemia of progressive renal failure with
recombinant human erythropoietin. N Engl J Med 1989;321:
158e63.
3. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG,
Downing MR, Egrie JC, et al. Recombinant human erythro-
poietin in anemic patients with end-stage renal disease: re-
sults of a phase III multicenter clinical trial. Ann Intern Med
1989;111:992e1000.
4. Freburger JK, Ng LJ, Bradbury BD, Kshirsagar AV,
Brookhart MA. Changing patterns of anemia management in
US hemodialysis patients. Am J Med 2012;125:906e14.
5. Chang YT, Pan SY, Lin SL. Seeking for a way to revive
erythropoietin production in chronic kidney disease.
J Formos Med Assoc 2013;112:657e8. http://dx.doi.org/
10.1016/j.jfma.2013.04.005.
6. Bernhardt WM, Wiesener MS, Scigalla P, Chou J,
Schmieder RE, Gunzler V, et al. Inhibition of prolyl hydroxy-
lases increases erythropoietin production in ESRD. J Am Soc
Nephrol 2010;21:2151e6.
7. Miyake T, Kung CK-H, Goldwasser E. Purification of human
erythropoietin. J Biol Chem 1977;252:5558e64.
8. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, et al.
Cloning and expression of the human erythropoietin gene.
Proc Natl Acad Sci 1985;82:7580e4.
9. Peces R, de la Torre M, Alca´zar R, Urra JM. Antibodies against
recombinant human erythropoietin in a patient with
erythropoietin-resistant anemia. N Engl J Med 1996;335:
523e4.
10. Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin an-
tibodies and pure red cell aplasia. J Am Soc Nephrol 2004;15:
398e406.
ESAs in CKD 911. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM,
Froissart M, et al. A peptide-based erythropoietin-receptor
agonist for pure red-cell aplasia. N Engl J Med 2009;361:
1848e55.
12. Fishbane S, Schiller B, Locatelli F, Covic AC,
Provenzano R, Wiecek A, et al. Peginesatide in patients
with anemia undergoing hemodialysis. N Engl J Med 2013;
368:307e19.
13. Macdougall IC, Provenzano R, Sharma A, Spinowitz BS,
Schmidt RJ, Pergola PE, et al. Peginesatide for anemia in
patients with chronic kidney disease not receiving dialysis. N
Engl J Med 2013;368:320e32.
14. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR,
Cotes PM. Effect of human erythropoietin derived from re-
combinant DNA on the anaemia of patients maintained by
chronic haemodialysis. Lancet 1986;328:1175e8.
15. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR,
Okamoto DM, et al. The effects of normal as compared with
low hematocrit values in patients with cardiac disease who
are receiving hemodialysis and epoetin. N Engl J Med 1998;
339:584e90.
16. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M,
et al. Correction of anemia with epoetin alfa in chronic kidney
disease. N Engl J Med 2006;355:2085e98.
17. Dru¨eke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC,
Tsakiris D, et al. Normalization of hemoglobin level in patients
with chronic kidney disease and anemia. N Engl J Med 2006;
355:2071e84.
18. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D,
Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes
and chronic kidney disease. N Engl J Med 2009;361:2019e32.
19. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S,
Seidenfeld J, et al. Recombinant human erythropoiesis-
stimulating agents and mortality in patients with cancer: a
meta-analysis of randomised trials. Lancet 2009;373:
1532e42.
20. Winkelmayer WC. Against treating all patients alike: lessons
from an FDA advisory committee meeting. J Am Soc Nephrol
2011;21:1e2.
21. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia
Work Group. KDIGO Clinical Practice Guideline for Anemia in
Chronic Kidney Disease. Kidney Int Suppl 2012;2:279e335.
22. Choukroun G, Kamar N, Dussol B, Etienne I, Cassuto-Viguier E,
Toupance O, et al. Correction of postkidney transplant ane-
mia reduces progression of allograft nephropathy. J Am Soc
Nephrol 2012;23:360e8.
23. Yeh PY, Liao FL, Lin SL. Reply to Comment on: Is the
renoprotective effect of erythropoietin in chronic kidney
disease a myth? J Formos Med Assoc 2013;113:63e4. http:
//dx.doi.org/10.1016/j.jfma.2013.03.005.
24. Park SH, Choi MJ, Song IK, Choi SY, Nam JO, Kim CD, et al.
Erythropoietin decreases renal fibrosis in mice with ureteral
obstruction: role of inhibiting TGF-b-induced epithelial-to-
mesenchymal transition. J Am Soc Nephrol 2007;18:
1497e507.
25. Heinze G, Kainz A, Horl WH, Oberbauer R. Mortality in renal
transplant recipients given erythropoietins to increase
haemoglobin concentration: cohort study. BMJ 2009;339:
b4018.
26. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S,
Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-
a dose and achieved hemoglobin outcomes. Kidney Int 2008;
74:791e8.
27. Raine AE. Hypertension, blood viscosity, and cardiovascular
morbidity in renal failure: implications of erythropoietin
therapy. Lancet 1998;331:97e100.
28. Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R,
Mendelssohn D, et al. Naturally occurring higher hemoglobinconcentration does not increase mortality among hemodial-
ysis patients. J Am Soc Nephrol 2011;22:358e65.
29. Hampl H, Hennig L, Rosenberger C, Amirkhalily M, Gogoll L,
Riedel E, et al. Effects of optimized heart failure therapy and
anemia correction with epoetin b on left ventricular mass in
hemodialysis patients. Am J Nephrol 2005;25:211e20.
30. Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ,
Nissenson AR, et al. Erythropoietin, iron depletion, and
relative thrombocytosis: A possible explanation for
hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis
2008;52:727e36.
31. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Beckie M,
Warnock DG. Time-dependent associations between iron and
mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:
3070e80.
32. Hung SC, Tarng DC. Bone marrow iron in CKD: correlation
with functional iron deficiency. Am J Kidney Dis 2010;55:
617e21.
33. Young B, Zaritsky A. Hepcidin for clinicians. Clin J Am Soc
Nephrol 2009;4:1384e7.
34. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV,
et al. Ferric gluconate is highly efficacious in anemic pa-
tients with high serum ferritin and low transferrin satura-
tion: results of the Dialysis Patients’ Response to IV Iron
With Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol
2007;18:975e84.
35. Vogel J, Gassmann M. Erythropoietic and non-erythropoietic
functions of erythropoietin (Epo) in mouse models. J Physiol
2011;589:1259e64.
36. Liu Y, Xu Y, Thilo F, Friis UG, Jensen BL, Scholze A, et al.
Erythropoietin increases expression and function of transient
receptor potential canonical 5 channels. Hypertension 2011;
58:317e24.
37. Brines M, Cerami A. Discovering erythropoietin’s extra-
hematopoietic functions: biology and clinical promise. Kid-
ney Int 2006;70:246e50.
38. Janmaat ML, Heerkens JL, de Bruin AM, Klous A, de Waard V,
de Vries CJ. Erythropoietin accelerates smooth muscle cell-
rich vascular lesion formation in mice through endothelial
cell activation involving enhanced PDGF-BB release. Blood
2010;115:1453e60.
39. Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin
and erythropoiesis-stimulating agents in tumor progression.
Clin Cancer Res 2011;17:6373e80.
40. Xue Y, Lim S, Yang Y, Wang Z, Jensen LD, Hedlund EM, et al.
PDGF-BB modulates hematopoiesis and tumor angiogenesis by
inducing erythropoietin production in stromal cells. Nat Med
2012;18:100e10.
41. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO,
Spivak JL, et al. American Society of Hematology/American
Society of Clinical Oncology clinical practice guideline update
on the use of epoetin and darbepoetin in adult patients with
cancer. Blood 2010;116:4045e59.
42. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J,
Burdmann EA, et al. Erythropoietic response and outcomes
in kidney disease and type 2 diabetes. N Engl J Med 2012;
363:1146e55.
43. Ifudu O, Feldman J, Friedman EA. The intensity of hemodi-
alysis and the response to erythropoietin in patients with end-
stage renal disease. N Engl J Med 1996;334:420e5.
44. Tarng DC, Huang TP, Chen TW, Yang WC. Erythropoietin
hyporesponsiveness: from iron deficiency to iron overload.
Kidney Int 1999;55:S107e18.
45. Lin CL, Huang CC, Yu CC, Wu CH, Chang CT, Hsu HH, et al.
Improved iron utilization and reduced erythropoietin resistance
by on-line hemodiafiltration. Blood Purif 2002;20:349e56.
46. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM,
Macdougall IC. Pentoxifylline improves hemoglobin levels in
10 S.-C. Hung et al.patients with erythropoietin resistant anemia in renal failure.
J Am Soc Nephrol 2004;15:1877e82.
47. Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC. Intravenous
ascorbic acid as an adjuvant therapy for recombinant eryth-
ropoietin in hemodialysis patients with hyperferritinemia.
Kidney Int 1999;55:2477e86.
48. Tarng DC, Huang TP. A parallel, comparative study of intra-
venous iron versus intravenous ascorbic acid for
erythropoietin-hyporesponsive anaemia in haemodialysis pa-
tients with iron overload. Nephrol Dial Transplant 1998;13:
2867e72.
49. Goldsmith D. A requiem for rHuEPOsdbut should we nail
down the coffin in 2010? Clin J Am Soc Nephrol 2009;2010(5):
929e35.50. Kliger AS, Fishbane S, Finkelstein FO. Erythropoietic stimu-
lating agents and quality of a patient’s life: Individualizing
anemia treatment. Clin J Am Soc Nephrol 2012;7:354e7.
51. Bright R. Cases and observations: illustrative of renal disease
accompanied by the secretion of albuminous urine. Guys Hosp
Rep 1836;1:338.
52. Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the
kidney in erythropoiesis. Nature 1957;179:633e4.
53. KDOQI National Kidney Foundation. KDOQI Clinical Practice
Guidelines and Clinical Practice Recommendations for Ane-
mia in Chronic Kidney Disease. Am J Kidney Dis 2006;47:
S11e145.
